第一金融网主办
»您现在的位置: 第一金融网 >> 金融焦点 >> 文传商讯 >> 正文

Boehringer Ingelheim and Lilly’s CAROLINA cardiovascular outcome trial for Trajenta meets primary endpoint of non-inferiority compared to glimepiride

2019/2/15 20:15:49  文章来源:文传商讯  作者:文传商讯
文章简介: Trajentademonstratesnoincreasedcardiovascularriskcomparedtoglimepirideinadultswithtype2diabetesandcardiovascularrisk Withamedianfollow-u

Trajenta demonstrates no increased cardiovascular risk compared to glimepiride in adults with type 2 diabetes and cardiovascular risk
With a median follow-up of more than 6 years, CAROLINA adds evidence to the long-term safety profile of Trajenta in a broad range of adults with type 2 diabetes

INGELHEIM, Germany & INDIANAPOLIS -- (BUSINESS WIRE) --

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined as non-inferiority of Trajenta® (linagliptin) vs glimepiride in time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3P-MACE).1,2

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190214005409/en/

CAROLINA® is the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor.1,2 The trial evaluated the cardiovascular safety of linagliptin (5 mg once daily) compared to the sulphonylurea glimepiride, on top of standard of care in 6,033 adults with type 2 diabetes and increased cardiovascular risk or established cardiovascular disease.1,2 The trial assessed linagliptin safety over the longest period ever studied in a DPP-4 inhibitor cardiovascular outcome trial, with a median follow-up of more than 6 years.1,2 The overall safety profile of linagliptin in CAROLINA® was consistent with previous data and no new safety signals were observed.3

People who have type 2 diabetes are at an increased risk of cardiovascular disease and, despite recent advancements in treatment options, cardiovascular disease remains the leading cause of death for this population.4 Together with CARMELINA®, the placebo-controlled cardiovascular outcome trial, which demonstrated long-term cardiovascular safety in adults with type 2 diabetes at high risk for heart and kidney disease,5 CAROLINA® confirms linagliptin’s long-term overall safety profile in a broad range of adults with type 2 diabetes.

“Many guidelines recommend early use of a diabetes treatment with cardiovascular benefit,” said Waheed Jamal, MD, Corporate Vice President and Head of Cardiovascular & Metabolic Medicine, Boehringer Ingelheim. “When other therapies such as DPP-4 inhibitors are considered for people with type 2 diabetes, physicians need a treatment with an established long-term safety profile. With these results, CAROLINA® expands our understanding of the long-term cardiovascular safety of linagliptin, which now has one of the most comprehensive datasets on the cardiovascular safety of a DPP-4 inhibitor.”

“These data provide further confidence in the well-established safety and tolerability profile of linagliptin for the treatment of adults with type 2 diabetes,” added Jeff Emmick, MD, PhD, Vice President, Product Development, Lilly Diabetes. “Linagliptin is an important option for physicians considering a DPP-4 inhibitor for their patients with type 2 diabetes. Boehringer Ingelheim and Lilly look forward to sharing the full results later this year.”

The full results of CAROLINA® will be presented on 10 June at the American Diabetes Association’s 79th Scientific Sessions in San Francisco, United States.

About CAROLINA®
CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) is a multi-national, randomised, double-blind, active-controlled clinical trial that involved 6,033 adults with type 2 diabetes from 43 countries at more than 600 sites observed for a median duration of more than 6 years.1,2 The trial included adults with early type 2 diabetes: adults with a median disease duration of 6.2 years, who either received no treatment at all, or received 1-2 glucose lowering agents (e.g. metformin).2 It was designed to assess the effect of Trajenta® (linagliptin) (5 mg once daily) compared to the sulphonylurea glimepiride (both added to stable background glucose-lowering medication and cardiovascular standard of care) on cardiovascular safety in adults with type 2 diabetes and increased cardiovascular risk or established cardiovascular disease.1,2 These people reflect patients that doctors typically see in their daily clinical practice.6

CAROLINA® was led by an academic trial steering committee and Boehringer Ingelheim and Eli Lilly and Company. CAROLINA® is the first DPP-4 inhibitor, active-comparator cardiovascular outcome trial.

About Trajenta® (linagliptin)
Trajenta® is a one dose, once daily DPP-4 inhibitor that provides significant efficacy in the reduction of blood sugar levels for adults with type 2 diabetes. It can be prescribed for adults with type 2 diabetes regardless of age, disease duration, ethnicity, body mass index (BMI), liver and kidney function.3 Trajenta® has the lowest kidney excretion rate of all DPP-4 inhibitors.7,8,9,10

About our cardiovascular outcome trials
Cardiovascular outcome trials are highly relevant, as cardiovascular disease is a major complication and the leading cause of death in type 2 diabetes. Worldwide, most people with type 2 diabetes die of a cardiovascular event.4 In 2015, Boehringer Ingelheim and Eli Lilly and Company announced results from the landmark cardiovascular outcome trial EMPA-REG OUTCOME® with the SGLT2 inhibitor empagliflozin, which reduced the relative risk of cardiovascular death by 38 percent in adults with type 2 diabetes and established cardiovascular disease, on top of standard of care.11,12,13,14,15 As a result, empagliflozin was the first oral type 2 diabetes medicine to have either a cardiovascular indication or data on the reduction of the risk of cardiovascular death included in the label in many countries.11,12

CAROLINA® is one of two cardiovascular outcome trials with the DPP-4 inhibitor, linagliptin.1,2 CAROLINA® and the CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk trial (CARMELINA®)5,16 provide one of the most comprehensive datasets on the long-term safety of a DPP-4-inhibitor.

CARMELINA® is a multi-national, randomised, double-blind, placebo-controlled clinical trial that involved 6,979 adults with type 2 diabetes from 27 countries at more than 600 sites observed for a median duration of 2.2 years.5,14 CARMELINA® studied the impact of Trajenta® (linagliptin) on cardiovascular and kidney safety in adults with type 2 diabetes at high risk for heart and/or kidney disease.5,14 The trial met its primary endpoint,17 with linagliptin demonstrating a similar cardiovascular safety profile compared to placebo when added to standard of care.5 CARMELINA® also included a key secondary composite endpoint,18 showing a similar kidney safety profile compared to placebo.5 The overall safety profile of linagliptin in CARMELINA® was consistent with previous data and no new safety signals were observed.3,5 CARMELINA® also showed a similar rate of hospitalisation for heart failure for linagliptin compared to placebo.5

To learn ore about CARMELINA®, please visit: https://www.carmelinatrial.com/

Please click on the following link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/CAROLINA-top-line

View source version on businesswire.com: https://www.businesswire.com/news/home/20190214005409/en/

CONTACT:

Tetsu Owari
Media & PR
Boehringer Ingelheim
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77 184867

Stephan Thalen
Global Business Communications
Lilly Diabetes
Email: stephan.thalen@lilly.com
Phone: +1 317 903 5640

分享到:
第一金融网免责声明:
1、本网站中的文章(包括转贴文章)的版权仅归原作者所有,若作者有版权声明的或文章从其它网站转载而附带有原所有站的版权声明者,其版权归属以附带声明为准。
2、文章来源为均为其它媒体的转载文章,我们会尽可能注明出处,但不排除来源不明的情况。转载是处于提供更多信息以参考使用或学习、交流、科研之目的,不用于 商业用途。转载无意侵犯版权,如转载文章涉及您的权益等问题,请作者速来电话和函告知,我们将尽快处理。来信:fengyueyoubian#sina.com (请将#改为@)。
3、本网站所载文章、数据、网友投稿等内容纯属作者个人观点,仅供投资者参考,并不构成投资建议,与第一金融网站无关。投资者据此操作,风险自担。如对本文内容有疑义,请及时与我们联系。
发表评论

【发表评论】(网友评论内容只代表网友观点,与本站立场无关!)
 姓 名:
 评 分: 1分 2分 3分 4分 5分
 评论内容:
验证码:   *
  • 请遵守《互联网电子公告服务管理规定》及中华人民共和国其他各项有关法律法规。
  • 严禁发表危害国家安全、损害国家利益、破坏民族团结、破坏国家宗教政策、破坏社会稳定、侮辱、诽谤、教唆、淫秽等内容的评论 。
  • 用户需对自己在使用本站服务过程中的行为承担法律责任(直接或间接导致的)。
  • 本站管理员有权保留或删除评论内容。
  • 评论内容只代表网友个人观点,与本网站立场无关。
  • 全站精选
    [新闻]  中国1月外币存款及贷款余额均创五个月新高
     央行:1月份对实体经济发放人民币贷款增3.57万亿
    [银行]  全球银行品牌价值排行榜出炉 中国银行业包揽前四
     渣打银行:将今年中国CPI预测由2.7%下调至2.0%
    [股票]  黄孟复:中国股市加在一起也就6个苹果
     A股杠杆图:配资公司会议室爆满 融资客重出江湖
    [基金]  基民常犯的五大定投误区 你中招了吗?
     中国QFII总额增至3000亿美元
    [保险]  重疾险销售理赔套路起底:广告噱头多 理赔看心情
     郭树清:加大保险资金财务性和战略性投资优质上
    [期货]  2月14日国内期油涨1.87%至441.8元 后市或震荡偏
     国内钢价窄幅下跌 铁矿石市场震荡盘整
    [股评]  周五机构一致看好的十大金股(1.31)
     明日最具爆发力六大牛股(1.31)
    [港股]  阿里巴巴成首个单季营收破千亿元中国互联网公司
     理財科技公司WeInvest進軍北亞市場並聘请Thomas
    [美股]  野心勃勃 谷歌宣布今年投资130亿美元在全美扩张
     美团点评和小米将被纳入MSCI新兴市场指数
    [外汇]  人民币对美元汇率中间价报6.8526元 下调124个基
     截至2018年12月末 中国外汇储备规模为30727亿美
    [债券]  中国央行:4月起中国债券将纳入彭博巴克莱债券指
     中国国债和政策性银行债券4月起纳入彭博巴克莱全
    [黄金]  2018年我国黄金产量401.119吨 黄金消费量1151.4
     黄永权:黄金未来走向预期思路!
    [理财]  刘谦微博回应:春晚魔术没有托儿
     人类能找到长寿密钥?消灭自由基、服用二甲双胍
    [信托]  民生信托撤回对乐视控股及贾跃亭执行申请 已追回
     前9月中国房企信托及发债超万亿人民币 “换马甲
    [房产]  中国第一高楼!深港国际中心拿到正式批复 高度确
     2019年楼市是否松绑成悬念 部分地区财政压力显现
    [汽车]  你中招了吗? 150万辆福特车召回 驾驶中可能自动
     马自达CX-5和CX-9再度入选《人车志》“十大最佳
  • 此栏目下没有推荐文章
  • | 设为首页 | 加入收藏 | 关于我们 | 友情链接 | 版权申明 | 文章列表 | 网站地图 | 征稿启事 | 广告服务 | 意见反馈 |

    Copyright©2006-2017 afinance.cn All Rights Reserved 版权所有·第一金融网 ,未经授权禁止复制或建立镜像,否则将依法追究法律责任!

    声明:我们不做任何形式的代客理财及投资指导,凡是以第一金融网名义做股票推荐的行为均属违法!

    广告商的言论与行为均与第一金融网无关!股市有风险,投资需谨慎。

    合作邮箱:fengyueyoubian@sina.com 合作电话:18678839953 点击这里给我发消息